ImmuneOnco Biopharmaceuticals (Shanghai) Valuation

Is 1541 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1541 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1541's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1541's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1541?

Key metric: As 1541 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 1541. This is calculated by dividing 1541's market cap by their current book value.
What is 1541's PB Ratio?
PB Ratio	4.4x
Book	CN¥600.24m
Market Cap	CN¥2.65b

1541 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	306.3x
Enterprise Value/EBITDA	-6.7x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 1541's PB Ratio compare to its peers?

The above table shows the PB ratio for 1541 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2.1x
2487 Cutia Therapeutics	2.2x	49.4%	HK$2.8b
2256 Abbisko Cayman	1.2x	-41.7%	HK$2.7b
2315 Biocytogen Pharmaceuticals (Beijing)	3.1x	n/a	HK$2.4b
2171 CARsgen Therapeutics Holdings	2.1x	24.6%	HK$3.3b
1541 ImmuneOnco Biopharmaceuticals (Shanghai)	4.4x	n/a	HK$2.9b

Price-To-Book vs Peers: 1541 is expensive based on its Price-To-Book Ratio (4.4x) compared to the peer average (3.4x).

Price to Book Ratio vs Industry

How does 1541's PB Ratio compare vs other companies in the HK Biotechs Industry?

3 Companies	Price / Book	Estimated Growth	Market Cap
2137 Brii Biosciences	0.3x	-7.4%	US$100.47m
2126 JW (Cayman) Therapeutics	0.3x	-1.8%	US$69.10m
6628 Transcenta Holding	0.4x	12.7%	US$45.77m

No more companies available in this PB range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 1541 is expensive based on its Price-To-Book Ratio (4.4x) compared to the Hong Kong Biotechs industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is 1541's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1541 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	4.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 1541's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Shineway Pharmaceutical Group

HK$6.4b

An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.

2877

HK$8.41

-5.4%

n/a

3SBio

HK$13.6b

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530

HK$5.77

-5.1%

-18.6%

United Laboratories International Holdings

HK$18.5b

An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.

3933

HK$10.18

-0.4%

31.4%